Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells by Pöllinger, Bernadette et al.
ARTICLE
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 206 No. 6  1303-1316
www.jem.org/cgi/doi/10.1084/jem.20090299
1303
Autoimmune diseases can affect most organs of 
the body including liver, heart, the endocrine 
system, the musculoskeletal apparatus, and the 
central nervous system (CNS). They commonly 
start off at a young age and then last throughout 
life, often resulting in severe disability. The fac-
tors that trigger the onset, modulate the course, 
and determine the clinical character of autoim-
mune diseases have remained obscure, a deficit 
of knowledge which sets limits to the design of 
specific and efficient therapies.
Yet there is increasing evidence that organ-
specific autoimmune diseases, such as rheuma-
toid arthritis, type 1 diabetes mellitus, and multiple 
sclerosis (MS), are the result of a pathogenic inter-
action of autoimmune T and B cells. There is 
substantial information on the role of T cells in 
organ-specific autoimmunity. Some act as ef-
fector cells attacking self-tissues, either directly 
or via recruiting accessory cells like macrophages. 
Other T cells regulate the time course of the 
response and still others provide help to auto-
antibody-producing B cells. The contribution of 
autoimmune B cells to the inflammatory patho-
genesis seems to be complex as well. Beyond 
producing humoral autoantibodies, B cells serve 
as APCs activating pathogenic T cells, and, 
through their capacity of releasing cytokines,   
B cells are involved in shaping local microenvi-
ronments favorable to evolving cellular auto-
immune responses.
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We describe new T cell receptor (TCR) transgenic mice (relapsing-remitting [RR] mice) 
carrying a TCR specific for myelin oligodendrocyte glycoprotein (MOG) peptide 92–106 in 
the context of I-As. Backcrossed to the SJL/J background, most RR mice spontaneously 
develop RR experimental autoimmune encephalomyelitis (EAE) with episodes often altering 
between different central nervous system tissues like the cerebellum, optic nerve, and 
spinal cord. Development of spontaneous EAE depends on the presence of an intact B cell 
compartment and on the expression of MOG autoantigen. There is no spontaneous EAE 
development in B cell–depleted mice or in transgenic mice lacking MOG. Transgenic T cells 
seem to expand MOG autoreactive B cells from the endogenous repertoire. The expanded 
autoreactive B cells produce autoantibodies binding to a conformational epitope on the 
native MOG protein while ignoring the T cell target peptide. The secreted autoantibodies 
are pathogenic, enhancing demyelinating EAE episodes. RR mice constitute the first spon-
taneous animal model for the most common form of multiple sclerosis (MS), RR MS.
© 2009 Pöllinger et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Deciphering the interactions between T and B cells in the 
spontaneous development of organ-specific autoimmune re-
sponses requires suitable animal models. Naturally occurring 
models are available for type 1 diabetes mellitus and systemic 
lupus erythematosus but not for autoimmunity in the CNS 
(1). Recently, we and others described a double-transgenic 
mouse model, which simulates opticospinal MS (OSMS) re-
markably well, a variant of which is also known as Devic’s 
disease (2, 3). These mice, termed opticospinal experimental 
autoimmune encephalomyelitis (EAE [OSE]) mice, express 
myelin oligodendrocyte glycoprotein (MOG)–specific recep-
tors on T and B cells and spontaneously develop demyelinat-
ing inflammatory disease at frequencies >50%. Like in human 
OSMS (4), the lesions in affected mice are restricted to optic 
nerve and spinal cord, and, in most cases, the disease takes a 
chronic progressive course without remissions and marked re-
lapses. It should, however, be noted that the type of MS that 
most prevalently affects Caucasian populations differs funda-
mentally from OSMS (5). Typically, MS starts out with a re-
lapsing-remitting (RR) course, where disease episodes may 
completely resolve only to be followed by a subsequent re-
lapse. In this disease variant, the pathogenic lesions, demyelin-
ating plaques, may be located throughout the CNS, thus 
causing the notoriously varied neurological defect patterns.
In this paper, we describe a new transgenic mouse model 
that spontaneously develops RR-EAE and, thus, recapitulates 
the “Western” variant of MS. Furthermore, and most impor-
tantly, we found that in these mice transgenic autoimmune   
T cells expand autoimmune B cells from the endogenous   
immune repertoire and guide them to produce antibodies 
against conformational epitopes of the MOG protein, which, 
together with complement, may initiate the destruction of 
MOG-expressing target cells.
RESULTS
New MOG-specific TCR transgenic SJL/J mice
We generated transgenic mice expressing a TCR specific for 
the rat/mouse MOG peptide 92–106 in the context of I-As. 
This TCR, which uses V8.3 and V4 genes, was derived 
from a MOG-specific encephalitogenic Th1-CD4+ T cell clone 
isolated from a WT SJL/J mouse immunized against recom-
binant rat MOG (rMOG; Fig. S1). We selected three founder 
lines differing in markedly distinct proportions of transgenic 
V8.3+/V4+ CD4+ T cells in central and peripheral immune 
repertoires (Fig. 1 A and Fig. S2). In low frequency TCR1586 
mice, 18% of single-positive CD4+CD8 thymocytes ex-
pressed the transgenic TCR. The proportion was 75% in   
medium frequency TCR1639 mice and 99% in high frequency 
TCR1640 mice (Fig. 1 A). In all three transgenic mouse lines, 
transgene expression levels in the peripheral immune system 
were proportional to the ones in the central thymic reper-
toires (Fig. S2).
The density of the transgenic TCR on the surface of ma-
ture CD4+ T cells in the spleen varied markedly (Fig. S2). 
Especially in high frequency TCR1640 spleens, T cells could 
be distinguished based on the low and high densities of sur-
face TCR (dim and bright TCR). The dim TCR population 
expressed higher levels of CD25 and CD69 and lower levels 
of CD62L (unpublished data).
Stimulation of nonimmunized transgenic spleen cells with 
rMOG or MOG92-106 peptide in vitro led to dose-dependent pro-
liferative responses (Fig. 1 B). Concomitant cytokine responses 
largely followed the proliferation pattern. Although the secretion 
of proinflammatory IFN-, IL-17, and antiinflammatory IL-10 
was similar in TCR1640 and TCR1639 lines, IL-2 secretion was 
higher in TCR1639 T cells. The Th2-related cytokines IL-4 and 
IL-5 were absent in nearly all samples tested (Fig. 1 C).
Spontaneous EAE in single- and double-transgenic SJL/J 
anti-MOG mice: RR course with varied clinical syndromes
While continuously backcrossing the line TCR1640 into the 
SJL/J background, we noted spontaneous EAE-like disease de-
veloping at a high frequency (Fig. 2 A and Table S1). In the 
eighth backcross generation, >80% of all females developed 
EAE within 160 d. During the same period, the EAE rate in 
males was >60%. EAE was rare in transgenic SJL/J mice with 
low frequency TCR1586 and surprisingly absent in medium fre-
quency TCR1639 mice and in Mog-deficient TCR1640 (TCR1640 
× Mog/) mice (Table S1).
We and others previously described a double-transgenic 
mouse strain, OSE mice (2, 3), which expressed a MOG-
specific TCR transgene, 2D2 (specific for MOG peptide   
35–55 in context of I-Ab), along with the gene coding for the 
rearranged IgH variable chain of the classical anti-MOG 
monoclonal antibody, 8.18-C5 (IgHMOG mice) (6). We have 
now  created  similar  double-transgenic  mice  by  mating 
TCR1640 SJL/J mice to IgHMOG on SJL/J background. Dou-
ble-transgenic TCR1640 × IgHMOG mice developed sponta-
neous EAE very similar to TCR1640 single transgenics, with 
some apparently minor differences. Almost all double-trans-
genic females came down with disease by 120 d of age, 
whereas males of the same age showed an EAE rate of <40%. 
This gender gap was highly significant but narrowed during 
the subsequent weeks (Fig. 2 A).
Figure 1.  Characterization of a new MOG-specific TCR transgenic SJL/J mouse. (A) Thymocytes from 8–10-wk-old TCR transgenic mice or NTLs 
were stained with antibodies to CD4, CD8, TCR-V4, and TCR-V8.3 and cells were analyzed by flow cytometry. Representative figures of three to seven 
analyzed mice are shown. Transgenic V8.3 and V4 are shown on cells gated as indicated, either CD4+/CD8 or CD4/ CD8+. (B) Proliferative response to 
recombinant MOG protein (rMOG) or MOG peptide 92–106 measured as 3H-thymidine incorporation. Splenocytes from TCR transgenic mice (8–10-wk-old 
healthy) were cultured with indicated concentrations of rMOG (top) and MOG92-106 (bottom). (C) Cytokine responses to rMOG. Indicated cytokines were 
measured in supernatants harvested 48 h after rMOG activation by ELISA. Pooled data from three independent experiments are shown. Error bars indicate 
SEM. B and C: TCR1640, n = 3; TCR1639, n = 3; TCR1586, n = 3; NTL, n = 2.
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The CNS disease spontaneously developing in TCR trans-
genic SJL/J mice differed dramatically from spontaneous OSE 
seen in OSE mice (2, 3). In TCR transgenic SJL/J mice, single-
transgenic TCR1640 mice, and double-transgenic TCR1640 × 
IgHMOG mice, disease was extremely variable both in course and 
We also crossed IgHMOG mice to the medium and low fre-
quency lines TCR1639 and TCR1586, respectively. Only 1 out 
of 17 medium frequency TCR1639 × IgHMOG mice displayed 
EAE and none of the low frequency TCR1586 × IgHMOG showed 
any clinical symptoms (Table S1).
Figure 2.  Spontaneous RR-EAE in TCR transgenic SJL/J mice. (A) Male and female single-transgenic TCR1640 compared with double-transgenic 
TCR1640 × IgHMOG mice. Shown is the spontaneous incidence of first signs of ataxia or classical EAE-like symptoms in TCR1640 (left) and double-transgenic 
TCR1640 × IgHMOG (right) mice. TCR1640 females (f), n = 12; males (m), n = 27; TCR1640 × IgHMOG females, n = 20; males, n = 26; TCR1640 × Mog/ mice,  
n = 6. Disease kinetic of genders in TCR1640 mice was not statistically significant (P = 0.304) but differed significantly between sexes of TCR1640 × IgHMOG 
mice (P = 0.0004). (B) Histological analysis of cerebellum and spinal cord from a sick TCR1640 mouse (RR mouse) with ataxia and classical paralysis. Cer-
ebellum (I–IV) and spinal cord (V–VIII) showed severe infiltration, demyelination, and axonal damage as visualized by immunohistochemistry using anti-
CD3 (I and V) and anti–Mac3 antibodies (II and VI), Luxol fast blue staining (III and VII), and Bielschowsky silver impregnation (IV and VIII). I, II, V, and VI 
were counterstained by hematoxylin and eosin (H&E). Magnification: ×17 (cerebellum) and ×30 (spinal cord). Bars, 1 mm. Data are representative of at 
least two independent experiments consisting of more than three mice per group.
Table I.  Spontaneous EAE in TCR transgenic SJL/J mice: course of disease
Mice (gender) RR (n) Progressive (n)
With full remission With partial remission
% % %
TCR1640 (f) 71.4 (5/7) 14.3 (1/7) 14.3 (1/7)
TCR1640 (m) 35.3 (6/17) 11.7 (2/17) 53 (9/17)
TCR1640 × IgHMOG (f) 43.7 (7/16) 25.0 (4/16) 31.2 (5/16)
TCR1640 × IgHMOG (m) 6.2 (1/16) 25.0 (4/16) 68.8 (11/16)
rMOG imm. SJL/J (f) 10.0 (1/10) 70.0 (7/10) 20 (2/10)
f, female; m, male; imm., immunized.JEM VOL. 206, June 8, 2009 
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clinical nature. Typically, in females EAE started with an RR 
course. Often, the first attacks resolved completely but were 
followed by further bouts. Intriguingly, individual EAE bouts 
often differed radically in their neurological defects. In a sub-
stantial number of cases, the initial bout was dominated by 
ataxia rather than by classical EAE defects. Affected mice 
were unable to walk along a straight line, deviating and fall-
ing to the side, but did not show limb weakness or paralysis 
(Video 1). In many cases, the mice recovered completely un-
til a first relapse, which commonly showed a completely dif-
ferent clinical picture, for example, hind limb paralysis as seen 
in typical EAE. Again, this second disease episode subsided, 
giving way to partial remission. Later disease episodes mostly 
showed classical paralytic EAE (Table I and Fig. S3).
Although there was no clear distinction between single- and 
double-transgenic SJL/J mice, EAE course differed between   
females and males. As detailed in Table I, RR disease was more 
common in females. A minority of female mice developed pro-
gressive EAE from the beginning, but more than half of the 
males developed primary progressive EAE.
CNS changes representing different clinical EAE episodes
The clinical deficiencies developing in affected mice were 
reflected by the location and character of underlying CNS 
lesions. Ataxic mice displayed large inflammatory and demy-
elinated lesions in cerebellum and brain stem (Fig. 2 B). In 
contrast, in mice suffering from conventional EAE, lesions 
were distributed throughout the spinal cord, brain stem, and 
optic nerve (Table S2).
Irrespective of their location within the CNS, the inflam-
matory lesions were characterized by numerous CD3+ T cells 
in the middle of a plethora of Mac3-positive activated macro-
phage-like cells (Fig. 2 B). The inflammatory infiltrates were 
embedded in large areas of demyelination and axon destruc-
tion. In line with their comparable clinical score, the histolog-
ical patterns were similar between TCR1640 single-transgenic 
and TCR1640 × IgHMOG double-transgenic mice (Table S2).
Cytofluorimetric analyses confirmed that, within the CNS, 
the major infiltrating inflammatory lymphocytes were CD4+ 
T cells and B cells together with a minor population of mac-
rophages and CD8+ T cells (Fig. 3, A–C), with only minor 
contributions from CD8+ T cells. Notably, most transgenic 
CD4+ T cells infiltrating the CNS were activated. Many cells 
expressed the activation marker CD25 and were CD62L nega-
tive (Fig. 3 D). Additionally, infiltrating CD4+ T cells ex-
pressed the activation markers CD44, VLA4, and ICOS 
(unpublished data). Furthermore, a high proportion (>65%) 
of CNS-infiltrating transgenic T cells partly down-modulated 
Figure 3.  Inflammatory cell infiltrates in RR-EAE lesions.  
(A–C) Cellular infiltrate into the CNS of sick TCR1640 mice (score 3) is com-
posed of macrophages, T cells, and B cells. CNS mononuclear cells were 
isolated from a sick TCR1640 mouse and stained against CD11b and CD45.1 
(A), together with CD8 and CD4 (B) or together with CD19 and B220  
(C). Cells in B and C were analyzed among gated CD45.1+CD11b cells (red 
region as indicated). (D–F) Activation and Th1/Th17 cytokine expression of 
infiltrating CD4+ T cells. (D) CNS infiltrate cells express CD25, but not 
CD62L, and partially down-modulate their TCR (V8.3 and V4). Activa-
tion status and TCR expression was compared between splenocytes (left) 
and CNS-isolated cells (right). (E) CD4+CD3+ T cells infiltrating the CNS of 
sick TCR1640 mice predominantly expressed the pathogenic TCR composed 
of V8.3 and V4 chains in a low expression level (TCRlow) compared with 
the spleen. Numbers indicate the percentage of stained cells in the re-
spective quadrant or region. (F) Intracellular cytokine staining after stimu-
lation with PMA/ionomycin in brefeldin A. Th1 (IFN-+/IL-17) and Th17 
(IFN-/IL-17+) cells are enriched in CNS infiltrates of sick TCR1640 (score 
3.5) mice compared with splenocytes. D–F were analyzed among gated 
CD45.1+CD4+ cells. Flow cytometry data are representative of three to five 
sick TCR1640 mice analyzed in three to five independent experiments.
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CD4 in diseased mice. Interestingly, we found no major differ-
ences between immunized WT SJL/J mice and TCR1640 mice, 
which suffered from classical paralytic EAE. In line with their 
clinical picture, ataxic mice showed higher expression levels of 
the analyzed genes in brain (which also includes cerebellum and 
brain stem) than did paralytic relapsed mice. Conversely, expres-
sion in spinal cord was higher in paralytic relapsed mice than in 
ataxic mice. Intriguingly, most analyzed factors were elevated 
even in healthy TCR1640 mice (score 0) as compared with 
healthy nontransgenic littermate (NTL) mice, likely indicating 
subclinical inflammation. Finally, during the remission phase, 
expression of all analyzed genes dropped down to similar values 
as in score 0–TCR1640 mice (Fig. S4).
Expansion of MOG-specific B cells in TCR1640  
single-transgenic SJL/J mice
Single-transgenic TCR1640 mice showed evidence of a strong 
MOG-specific B cell response. Spontaneous EAE lesions of sin-
gle-transgenic TCR1640 animals displayed prominent deposits of 
Ig and some activated complement (Fig. 4). Furthermore, the 
inflamed CNS tissue contained, besides CD4+ and CD8+ lym-
phocytes, substantial numbers of B cells (5–40% of infiltrated 
lymphocytes) expressing CD19 or B220 as revealed by immuno-
cytochemistry and flow cytometry (Fig. 3 and Fig. 4 E).
their transgenic V4 and V8.3 determinants, which is in 
contrast to peripheral splenic populations, where the modu-
lated subpopulations comprised less than half of the entire 
transgenic CD4+ T cell subset (Fig. 3 E).
In agreement with previous EAE studies (7–10), we found 
CNS-infiltrating Th1 (IFN-+/IL-17) and Th17 (IFN-/
IL-17+) cells. Compared with spleen, Th17 cells were enriched 
in CNS threefold and Th1 cells more than twofold (Fig. 3 F). 
A substantial part of the activated CD4+CD25+ infiltrate T cells 
express transcription factor Foxp3, a marker of regulatory   
T cells (not depicted) (11).
Next, we measured the cytokine milieu in brain and spinal 
cord of TCR1640 mice in different disease stages by real-time 
PCR in comparison to rMOG immunized SJL/J mice (Fig. S4). 
Most cytokines followed an infiltration pattern proportional to 
CD4 expression. As expected from our infiltrate analysis (Fig. 3), 
we found expression of both IFN- and IL-17 in diseased mice. 
In accordance with this, TNF- and IFN- inducible protein 
10 (IP-10/CXCL10) were strongly up-regulated during disease. 
Of the Th2 cytokines analyzed (IL-4, IL-5, and IL-13), only   
IL-5 was at measurable levels. This cytokine may support B cell 
proliferation, differentiation, and antibody secretion (12). The 
levels of the regulatory cytokine IL-10 and of the T reg cell 
transcription factor FoxP3 paralleled the observed expression of 
Figure 4.  Ig deposition and B cell infiltrates in spinal cord of sick TCR1640 × IgHMOG and TCR1640 mice. (A–D) Histological analysis of spinal cord 
using anti-Ig antibodies shows deposition of Ig in sick TCR1640 × IgHMOG (A and B) and TCR1640 (C and D) mice (B and D show magnifications of marked 
areas in A and C, respectively). (E) Anti-B220 staining revealed some B cells among cellular infiltrates in sick TCR1640 mice. (F) Deposition of complement 
C9neo within CNS lesions of TCR1640 mice. Mononuclear cells were stained with H&E. Magnifications: A and C, ×50; B, ×425; D and E, ×200; F, ×450. Bars: 
(A and C) 1 mm; (B and D–F) 100 µm. Data are representative of at least two independent experiments consisting of more than three mice per group.JEM VOL. 206, June 8, 2009 
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Double-transgenic TCR1640 × IgHMOG animals showed an 
anti-MOG antibody response dominated by the transgene-
specific allotype Igha. In addition, however, a minor part of the 
MOG-specific antibodies expressed the endogenous nontrans-
genic Ighb allotype (Fig. 5 B). Both antibody species were 
switched from IgM to IgG1 (Fig. 5, A and B).
Single-transgenic TCR1640 mice also produced anti-MOG 
autoantibodies (of endogenous Ighb-allotype) reaching titers sim-
ilar to those from WT mice immunized with rMOG (Fig. 6 A). 
The anti-MOG Igs were mainly of IgG1 and IgG2a/b isotypes, 
with very little IgM. The spontaneously appearing anti-MOG 
transgenic high frequency TCR1640 mice formed autoantibodies 
irrespective of their EAE status. This contrasted with low fre-
quency single-transgenic TCR1586, where anti-MOG autoanti-
bodies were noted solely in the few animals with spontaneous 
EAE but not in resistant mice (Fig. 6 B). Also, mice of the EAE-
resistant medium frequency line TCR1639 did not produce spon-
taneous MOG-specific antibodies. Development of spontaneous 
MOG antibodies was dependent on the presence of the autoan-
tigen. Sera of MOG-deficient TCR1640 mice (bred on the Mog-
deficient [Mog/] background [reference 13]) did not contain 
any MOG-specific antibodies (Fig. 6 B). The B cell response in 
TCR1640 mice was specific to MOG and did not extend to other 
autoantigens (Fig. 6 C). In single-transgenic TCR1640 mice, au-
toantibodies became demonstrable from 5 wk of life and, in our 
series of measurements, persisted up to 9–10 wk, but very young 
mice, up to 4 wk of age, had no anti-MOG Igs (IgG1 and 
IgG2a/b isotypes) (Fig. 6 D).
Contribution of endogenous B cells and anti-MOG 
autoantibodies to RR spontaneous EAE
There is evidence that only autoantibodies directed against 
conformational epitopes, not linear epitopes, are involved in 
the pathogenesis of EAE (14) and that SJL/J mice, but not 
C57BL/6 mice, are able to produce such antibodies upon im-
munization with rMOG in CFA (15). The anti-MOG auto-
antibodies formed spontaneously in TCR1640 mice also bound 
to correctly folded MOG expressed on the surface of trans-
duced EL4 cells and, thus, behaved like the classical anticon-
formational MOG mAb 8.18-C5 and its H chain transgene in 
TCR1640 × IgHMOG mice (16) (Fig. 7 A). Binding of autoan-
tibodies from TCR1640 and sick TCR1586 mice to EL4-MOG 
cells (dilutions of 1:20 and 1:200) followed by rabbit comple-
ment (Fig. 7 B) resulted in the specific lysis of the target cells. 
Sera from healthy TCR1586 and TCR1639 or Mog-deficient 
TCR1640 did not support lysis (unpublished data).
We confirmed the pathogenic potential of antibodies, in 
vivo. We immunized WT SJL/J mice with a low dose of PLP 
139–151 and with incipient clinical EAE symptoms (between 
scores 0.5 and 1), we transferred serum either from TCR1640 
mice (high titers of anti-MOG antibodies documented by 
ELISA) or NTLs, and compared the effects with the standard 
Figure 5.  MOG-specific antibodies in double-transgenic TCR1640 × 
IgHMOG and single TCR transgenic mice. (A) MOG binding allotype a 
autoantibodies were detected by ELISA in sera of indicated groups (each 
five to six mice). (B) Spontaneous anti-MOG IgG1 allotype b antibodies in 
TCR1640 and TCR1640 × IgHMOG but not in NTL (n = 5 for each group). Sera 
at the indicated dilutions were incubated with plates precoated with 
rMOG. Bound anti-MOG Ig was detected by allotype-specific antibodies as 
indicated. Mean absorbance at OD 405 nm is shown. Error bars indicate 
SEM. Data are representative of two to three independent experiments.
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TCR1640 mice were treated with anti-CD20 or isotype con-
trol (mouse IgG2a) every 2 wk starting on day 3. This proto-
col removed the B cells from peripheral blood, as well as 
spleen and lymph nodes, but left significant numbers of B cells 
in the bone marrow (Fig. S5, A and B). B cell depletion went 
along with either complete or partial loss of anti-MOG IgG1 
anti-MOG monoclonal antibody 8.18C-5. In mice that had re-
ceived TCR1640 serum, we noted a statistically significant increase 
in EAE severity similar to that of 8.18C-5 mAb (Fig. 8 A).
To examine the importance of B cells in the develop-
ment of spontaneous EAE, we depleted B cells in TCR1640 
mice using a monoclonal mouse anti–mouse CD20 antibody. 
Figure 6.  MOG-specific antibodies in single TCR transgenic mice. (A) Endogenous MOG binding antibodies of allotype b were measured by ELISA in 
sera of NTLs, healthy and sick TCR1640, and rMOG-immunized WT SJL/J (n = 6 for each group). (B) Anti-MOG Igs of IgG1b isotype are formed in TCR1640 and sick 
TCR1586 but not in TCR1639 or TCR1586 mice. Control NTLs, as well as TCR1640 mice deficient for MOG (Mog/), are devoid of MOG binding autoantibodies (each 
three to five mice per group). (C) Autoantibodies in sera from TCR1640 mice are specific for MOG. Anti-MOG Ig antibodies, but not anti-MBP or anti–DNA-
specific antibodies, were detected by ELISA in sera from TCR1640 mice (1/50 diluted) using IgG1b-specific antibodies (n = 5). (D) Appearance of anti-MOG IgG1b 
and IgG2a/bb in TCR1640 mice by 5 wk of age. MOG binding antibodies were measured in 1/100 diluted sera from mice of different ages, each with three to five 
mice per group. Sera at the indicated dilutions were incubated with plates precoated with rMOG. Bound anti-MOG Ig was detected by allotype-specific anti-
bodies as indicated. Mean absorbance at OD 405 nm is shown. Error bars indicate SEM. Data are representative of two independent experiments.JEM VOL. 206, June 8, 2009 
ARTICLE
1311
The course and clinical expression of autoimmune dis-
eases are determined by diverse factors, both genetic and en-
vironmental. Indeed, SJL/J mice are predisposed to develop 
fluctuating disease. Depending on the protocol applied, active 
immunization against encephalitogenic proteins may trigger 
RR disease (18). Clearly, this response pattern is facilitated by 
distinct regulatory genes (19), which may also influence spon-
taneous EAE developing in RR mice. So far, our breeding 
results suggest that B10.S mice, which have a distinct genetic 
background but share the MHC and the TCR transgene with 
SJL/J RR mice, very rarely develop spontaneous EAE, and in 
the few cases observed, the disease took a chronic rather than 
RR course (unpublished data).
Most variants of induced EAE present a stereotypical clini-
cal syndrome with motor deficiencies starting at tail and hind 
limbs and progressing cranially with ongoing disease. Histolog-
ically, this clinical picture is reflected by a caudocranial gradient 
of inflammatory lesions (20). In a few models, however, addi-
tional parts of the CNS are affected. For example, in C57BL/6 
mice, MOG-induced EAE has a predilection to affect the optic 
nerve (2, 3), and cerebellar disease was noted in further anti-
gen/mouse combinations (21, 22). Our RR mouse models are 
the first to show immune attacks against different CNS parts in 
subsequent inflammatory relapses. They thus provide a unique 
paradigm to study the mechanisms underlying the targeting of 
MS lesions within the CNS during ongoing disease.
serum autoantibodies (Fig. S5 C). Within an observation pe-
riod of up to 30 wk, only one out of nine anti-CD20–treated 
mice presented mild and transient EAE symptoms, whereas in 
mice receiving control antibody, spontaneous EAE was noted 
in >85% of the cases (Fig. 8 B and Table S3).
DISCUSSION
The RR mouse, as described in this paper, is the first transgenic 
mouse model that recapitulates the major features of RR-MS, 
the most prevalent type of human inflammatory demyelination. 
The disease starts spontaneously and, in contrast to OSE mice 
described previously (2, 3), in most cases takes an RR course, 
with clinical signs differing between individual bouts. Impor-
tantly, development of spontaneous disease goes along with the 
expansion of myelin autoimmune B cells from the endogenous 
immune repertoire.
Spontaneous RR-EAE
RR mice are transgenic SJL/J mice expressing at high frequency 
a TCR specific for MOG peptide 92–106 in the context of I-As. 
RR mice differ substantially from previously created transgenic 
SJL/J mice expressing TCRs recognizing a dominant peptide of 
PLP (17). These animals, kept under specific pathogen-free con-
ditions, developed spontaneous disease but, in contrast to RR 
mice, the disease was mostly progressive without remissions and 
subsequent relapses.
Figure 7.  MOG-specific autoantibodies bind MOG-expressing cells and activate complement. (A) Binding of anti-MOG Ig from indicated mice to 
correctly conformed MOG on the cell surface of transduced EL4 cells (EL4-MOG) shown by flow cytometry. EL4 cells (top) and MOG-expressing EL4-MOG 
cells (bottom) were incubated with 1/200 diluted sera obtained from the indicated mice or 0.5 µg/ml 8.18-C5 mAb. Bound antibodies were detected by 
FACS using biotinylated anti–IgG1-specific antibody (allotype unspecific) and streptavidin-PE (SA-PE). A representative plot of three independent experi-
ments is shown. (B) Complement activating capability of MOG binding antibodies in sera from transgenic mice. EL4 and EL4-MOG cells were incubated 
with sera (1/20 and 1/200 diluted) obtained from the indicated mice, each with three to five per group. Complement activating capability was measured 
by cell lysis using propidium iodide (PI) staining after incubation of sera-bound EL4 cells with rabbit complement. Background values were subtracted, 
and shown are mean values with the SEM of one experiment representative of three similar experiments.1312 SPONTANEOUS RELAPSING-REMITTING EAE | Pöllinger et al.
than MOG p92-106, has not been patent in spontaneous dis-
ease of our RR mice.
Expansion of MOG-specific B cells  
from endogenous repertoire
As described recently, in the C57BL/6 OSE model, MOG-
reactive TCR transgenic T cells require the presence of MOG-
specific B cells to kindle spontaneous EAE at high frequency. 
In this model, the MOG-specific B cells were transgenic with 
their germline IgJ region replaced by the rearranged H chain of 
a MOG-specific mAb (2, 3).
Based on these previous observations, we initially created 
double-transgenic mice by crossing our new MOG TCR 
Several investigators reported that in RR-EAE actively 
induced by immunization with encephalitogenic peptides, 
relapses went along with the T cell reactivity against new epi-
topes (23), a phenomenon termed “determinant spreading” 
by Lehmann et al. (24). Recent work by McMahon et al. (25) 
suggests that in actively induced chronic EAE, initial bouts of 
CNS  inflammation  result  in  the  induction  of  professional 
APCs within or near the affected CNS target tissue. By taking 
up myelin antigens and presenting crucial epitope compo-
nents to newly arrived naive autoreactive T cells, the reper-
toire of target autoantigens spreads (25). It should, however, 
be mentioned that determinant spreading, i.e., recruitment of 
potentially encephalitogenic T cells specific for epitopes other 
Figure 8.  B cells and anti-MOG antibodies are essential for spontaneous EAE. (A) Spontaneously developed MOG-specific autoantibodies from 
TCR1640 mice have pathogenic potential. EAE was induced in WT SJL/J mice by low-dose PLP 139–151 immunization. Serum from TCR1640 mice, NTL mice, 
or 8.18c5 mAb were transferred after mice showed first clinical symptoms. Serum from TCR1640 mice significantly increased disease severity in recipient 
mice compared with serum from NTL mice. Error bars indicate SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data were pooled from two independent ex-
periments, each six to seven per group. (B) B cell depletion protects TCR1640 mice from spontaneous EAE. B cells were depleted from TCR1640 mice by twice 
weekly injections of anti-CD20 antibodies from day 3 after birth, and control mice received mouse IgG2a antibodies. The development of spontaneous 
EAE was monitored regularly. Although 85% of isotype control antibody-treated mice developed spontaneous EAE, treatment with CD20 antibody pro-
tected TCR1640 mice from disease development. Shown are the disease course (left) and the spontaneous EAE incidence (right) of TCR1640 mice treated with 
these antibodies. Data were pooled from two independent experiments, each with six to seven per group.JEM VOL. 206, June 8, 2009 
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virus-specific B cell was noted in the presence of high num-
bers of virus-specific transgenic CD4+ T cells and a viral 
pseudo-autoantigen expressed throughout the organism in 
cell types including DCs and macrophages (30).
Several mechanisms could be involved in MOG-specific 
B cell expansion. MOG-specific T cells could intrude into the 
naive CNS and create immunogenic conditions that allow the 
activation and expansion of naive B cells in the local milieu. 
This scenario has been forwarded recently as an explanation of 
epitope spreading in actively induced EAE (25). Alternatively, 
immunogenic MOG and/or myelin debris could be trans-
ported to local lymph nodes, either as cell-free material or by 
phagocytes, to be presented there to autoreactive B cells (31). 
Although MOG is predominantly expressed in the CNS, its 
messenger RNA was also found in some non-CNS organs, 
such as thymus, spleen, and liver (13, 32, 33), and low protein 
levels were found in the peripheral nervous system (34). Pre-
sentation of very low amounts of peripherally available MOG 
remains, at least in theory, an alternative mechanism of B cell 
expansion in RR mice.
Finally, animal models with spontaneously developing EAE 
show promise for the discovery of new drugs and the validation 
of existing medications. Thus, the opticospinal type of EAE de-
scribed previously may represent essential features of human 
OSMS/Devic’s disease (2), a disease variant which is rarely found 
in high prevalence populations. The spontaneous RR-EAE, 
with its conspicuous variation of neurological deficiencies, will 
provide a model for the most frequent type of MS, as it is seen 
typically in early phases of the disease.
MateRials and Methods
Mice. SJL/J mice were purchased from Charles River Laboratories. Mog KO 
mice (13) were backcrossed into SJL/J for seven generations, crossed with 
TCR1640 transgenic SJL/J mice, and then intercrossed to generate TCR1640 
transgenic Mog KO mice. All mouse strains were bred in the animal facilities 
of the Max Planck Institute of Neurobiology (Martinsried, Germany).
Generation of TCR transgenic mice. TCR donor clone (C3) was   
selected from a panel of MOG-specific T cell clones (series SL48) derived 
from a SJL/J mouse immunized with rMOG in CFA. The encephalitogenic 
clone C3 uses V8.3 along with V4 and recognizes MOG92-106 bound 
to I-As. Total RNA of clone C3 was isolated by TRI reagent extraction 
(Sigma-Aldrich) and, after DNase I treatment, was converted into comple-
mentary DNA (cDNA) using hexanucleotide primers and Superscript II re-
verse transcription (Invitrogen). The rearranged cDNA of TCR-8.3 and 
TCR-4 chains were amplified with the following primer pairs: TCR-8.3 
sense with SalI restriction site, 5-AGGTGTCGACCTTCCATGAACAT-
GCGTCCTGACACC-3; TCR- C terminus with BamHI restriction 
site, 5-ATAGGATCCTCAACTGGACCACAGCCTCAGC-3; TCR-4 
sense with SalI restriction site, 5-AGGTGTCGACTGACACTGCTATGG-
GCTCCATTTTCCTC-3; and TCR- C2 terminus with BamHI restriction 
site, 5-ATAGGATCCGGGTGAAGAACGGCTCAGGATGC-3 (all syn-
thesized at Metabion). The rearranged TCR-8.3 and TCR-4 chains from 
C3 cDNA were verified by sequencing. To eliminate a XhoI restriction   
site (CTC GAG) in TCR-4 at aa 116, GAG was changed into GAA, both   
coding for glutamate, using a site-directed mutagenesis kit (Agilent Tech-
nologies) with the following primer pair: V4 XhoI–Mut sense, 5-CCAGA-
CTGACTGTTCTCGAAGATCTGAGAAATGTG-3; and V4 XhoI–Mut,   
5-CACATTTCTCAGATCTTCGAGAACAGTCAGCTGG-3.  The 
amino acid sequence of the CDR3 regions is as follows: TC8.3, LYY 
transgenic SJL/J strain with MOG-specific B cell knock-in 
SJL/J mice. These mice presented with spontaneous RR-EAE 
at high frequency. Less expected spontaneous EAE was noted 
also in TCR single-transgenic SJL/J mice with a high propor-
tion of MOG-reactive CD4 T cells but without transgenic B 
cells. It turned out that in these TCR single-transgenic mice, 
MOG-specific B cells were expanded from the endogenous   
B cell compartment. Substantial numbers of B cells were ob-
served to invade the inflammatory lesions, and there were 
heavy local deposits of Ig along with some activated comple-
ment. Most importantly, TCR single transgenics produced 
high titers of anti-MOG autoantibodies of IgG1 and IgG2 iso-
types, which bound to correctly conformed membrane bound 
autoantigen, destroyed MOG-expressing target cells, and, thus, 
have demyelinating potential (16).
MOG-reactive B cells are essential for the spontaneous 
development of RR-EAE. Depletion of B cells by treatment 
with anti-CD20 mAb profoundly suppressed RR-EAE when 
started at young age. Treatment of adult mice produced much 
more inconsistent results, a phenomenon which was recently 
noted in other investigations in actively induced EAE (26).
B cells contribute to immune and autoimmune responses by 
secreting humoral antibodies, by acting as APCs, and by releas-
ing cytokines. RR mice, both single and double transgenic, pro-
duce MOG-specific autoantibodies that share their dominant 
isotype, IgG1, with the original demyelinating anti-MOG mAb 
8.18-C5 and that, in vivo, aggravate EAE when transferred i.v. 
(27). Importantly, we found large Ig deposits in the demyelinat-
ing lesions of single- and double-transgenic RR mice. At least 
part of these antibodies may have been produced by local infil-
trating B cells. In fact, B cells isolated from CNS infiltrates were 
found to secrete anti-MOG antibodies at high levels.
Beyond autoantibody secretion, MOG-specific B cells pro-
foundly influence autoimmune responses by directly interacting 
with autoimmune T cells. In OSE mice, as well as in TCR1640 
× IgHMOG mice (unpublished data), MOG-specific B cells con-
centrate highly diluted MOG and present the antigen to MOG-
reactive T cells. Hence, antigen-presenting B cells may contribute 
to the initiation and progression of spontaneous EAE. But, in 
addition, B cells may act into the opposite direction; they were 
shown to limit EAE by releasing IL-10 (28) and by influencing 
function of regulatory T cells (29).
The spontaneous recruitment and expansion of autoim-
mune B cells from the endogenous repertoire by organ-specific 
autoimmune T cells in the absence of exogenous autoantigen 
represents a mechanism of autoimmunity that has not yet been 
described. The MOG-specific B cell expansion process criti-
cally requires the presence of the endogenous target autoanti-
gen, as Mog-deficient TCR transgenic SJL/J mice never 
produced anti-MOG autoantibodies, nor did they develop 
spontaneous RR-EAE.
The role of endogenous MOG is intriguing, considering 
that this target autoantigen is predominantly confined to the 
CNS tissues, which are largely inaccessible to circulating T 
and B cells. This hidden localization distinguishes the RR 
mouse paradigm from transgenic mice, where activation of   1314 SPONTANEOUS RELAPSING-REMITTING EAE | Pöllinger et al.
fluorochrome-labeled antibodies were purchased from BD or eBioscience: 
CD3 (145-2C11), CD4 (RM4-5), CD8 (53–6.7), V8.3 (B21.14), V4 
(KT4), CD11b (M1/70), CD45.1 (A20), CD19 (1D3), B220 (RA3-6B2), 
CD62L  (MEL-14),  CD25  (PC61),  IFN-  (XMG1.2),  IL-17  (TC11-
18H10), and IgG1 (A85-1).
Histological analysis. Brain and spinal cord tissue from mice fixed by perfu-
sion with 4% phosphate buffered paraformaldehyde were embedded in paraf-
fin. Paraffin sections were stained with H&E, with Luxol fast blue for myelin, 
and by Bielschowsky silver impregnation for visualization of neurons and ax-
ons. Adjacent serial sections were stained by immunocytochemistry, using pri-
mary antibodies directed against CD3, B220, Mac-3, mouse Ig, and rat/mouse 
complement C9 neoantigen. Immunocytochemistry was performed with a bi-
otin avidin technique.
Quantitative real-time TaqMan PCR analysis. Real time quantitative   
PCR analysis was performed as previously described (2). Quantification of the   
expression of mouse immune and housekeeping genes was performed by 
Taqman PCR using the following primer/probe combinations: GAPDH   
sense, 5-TCACCACCATGGAGAAGGC-3; GAPDH antisense, 5-GCT-
AAGCAGTTGGTGGTGCA-3; GAPDH probe, 5-ATGCCCCCATG-
TTTGTGATGGGTGT-3; mIL-5 sense, 5-CCGCTCACCGAGCTCT-
GTT-3; mIL-5 antisense, 5-AGATTTCTCCAATGCATAGCTGG-3; 
IL-5 probe, 5-CAGGAAGCCTCATCGTCTCATTGCTTGT-3; mIL-
10 sense, 5-CAGAGAAGCATGGCCCAGAA-3; mIL-10 antisense, 5-
TGCTCCACTGCCTTGCTCTT-3; mIL-10 probe, 5-TGAGGCGCT-
GTCATCGATTTCTCCC-3; mIL-17 sense, 5-AACTCCCTTGGCG-
CAAAAGT-3; mIL-17 antisense, 5-GGCACTGAGCTTCCCAGATC-
3; mIL-17 probe, 5-CCACGTCACCCTGGACTCTCCACC-3; mCD4 
sense, 5-CGTTTCCTCTCATCATCAATAAACTTA-3; mCD4 antisense, 
5-GGCTGGTACCCGGACTGAAG-3; mCD4 probe, 5-CACTTTG-
AACACCCACAACTCCACCTCCT-3; TCR-V8.3 sense, 5-CCAC-
GCCACTCTCCATAAGAG-3;  TCR-V8.3  antisense,  5-CAGTAG-
TACAGGCCAGAGTCTGACA-3; TCR-V8.3 probe, 5-CCTGAGC-
CAAAATACAGCGTTT-3; TCR-V sense, 5-TGATGACTCGGCC-
ACATACTTC-3; TCR-V4 antisense, 5-AGCAGCTCCTTCCATCT-
GCAGAAGTCC-3; TCR-V4 probe, 5-TGCCAGCAGCCAAGAACG-
GACAGAT-3; mFoxP3 sense, 5-AGGAGAAGCTGGGAGCTATGC-3; 
mFoxP3 antisense, 5-TGGCTACGATGCAGCAAGAG-3; and mFoxP3 
probe, 5-AAGGCTCCATCTGTGGCCTCAATGGA-3. IFN-, TNF-, 
IL-4, IL-13, and IP-10 Taqman probes were synthesized as described in 
Giulietti et al. (37).
Cell surface serum binding and complement assay. For EL4-MOG cells, 
the mouse Mog cDNA was cloned into the retroviral vector pLXSN (Clontech 
Laboratories, Inc.) and transformed into a GP+E-86 packaging cell line. Virus-
containing supernatant was used to stably transduce the mouse EL4 lymphoma 
cell line. EL4 and MOG-transduced EL4 cells (EL4-MOG; 2 × 105/well) were 
incubated with sera at the indicated dilutions for 30–45 min at 4°C, washed in-
tensively, and thereafter either stained with biotinylated anti–mouse IgG1 (BD) 
and streptavidin–PE diluted at 1/150 and PI at 1 µg/ml or incubated with 
LOW-TOX-M rabbit complement (Cedarlane Laboratories) at a 1/10 dilution 
for 90 min at 37°C and thereafter analyzed for lysis by staining with PI. For 
analysis of binding only live (PI) cells are gated for the histograms.
Depletion of B cells. For B cell depletion, 20 µg of mouse anti–mouse CD20 
(18B12; IgG2a; Biogen Idec) (38) or IgG2a control antibody (Sigma-Aldrich) 
was injected s.c. into 3-d-old TCR1640 mice. 2 wk later, pups were injected with 
80 µg and, at 4 wk old, with 250 µg of respective antibodies. Injections were re-
peated thereafter at 2-wk intervals with 250 µg of respective antibodies.
Serum transfer. Sera were obtained through retroorbital bleeding from TCR1640 
or NTL. WT SJL/J mice were immunized with 100 µg PLP139-151 in 5 mg/ml 
CFA. 200 ng of Pertussis toxin was injected on days 0 and 2. When mice showed 
clinical EAE signs (score 1.0), they received i.p. injections of 250 µl TCR1640 
serum or NTL serum or 8.18c5 mAb three times at 48-h intervals.
CALSGGNNAPR FG (V8.3J4); and TCR-4, CASS QERT DSAE TLY 
(V4D1J2.3C2). The complete rearranged TCR chains were cloned into   
the pHSE3 vector (35), leading to expression under the control of the transgenic 
MHC class I H2-Kb promoter. XhoI-linearized TCR-containing plasmids were 
coinjected into the pronuclei of fertilized FVB oocytes. Transgenic founders 
were identified by PCR using a specific primer for C3 V-J or V-J in 
combination with a pHSE3-specific primer (TCR- chain: mTCR-V8.3-
CDR3  sense,  5-CTCCATAAGAGCAGCAGCTCC-3,  and  hu  -globin   
antisense,    5-CGTCTGTTTCCCATTCTAAACTGTACC-3;    TCR-   chain:   
PH-2Kb sense, 5-CTGGATATAAAGTCCACGCAGCC-3, and TCR-
V4-CDR3 antisense, 5-CAATCTCTGCTTTTGATGGCTCAAAC-3). 
Transgenic mice were backcrossed for at least eight generations into the 
SJL/J background.
EAE induction and scoring. Mice were injected s.c. at the back with 200 µl 
of recombinant MOG (200 µg), which was emulsified in Freund’s adjuvant and 
supplemented with 3 mg/ml Mycobacterium tuberculosis (strain H37Ra). 200 ng 
of pertussis toxin was injected i.p. on days 0 and 2 after immunization. Clinical 
scoring of classical paralytic EAE was performed as follows: score 0, healthy; 1, 
flaccid tail; 1.5, flaccid tail and impaired righting reflex; 2, impaired righting re-
flex and hind limb weakness; 2.5, one hind leg paralyzed; 3, both hind legs par-
alyzed with residual mobility in both legs; 3.5, both hind legs completely 
paralyzed; 4, both hind legs completely paralyzed and beginning front limb par-
alysis; and 5, moribund or death of the animal after preceding clinical disease. 
Ataxic scoring was as follows: score 0, healthy; 1, mouse partly tilted, feet fall 
into cage fence; 2, tilted and tumbles; 3, mouse heavily tilted and moves in cir-
cles; 4, inability to walk, is only rolling. and 5, moribund. All animal procedures 
used were in accordance with guidelines of the committee on animals of the 
Max Planck Institute of Neurobiology and with the license of the Regierung 
von Oberbayern (Munich, Germany).
Antigens. Recombinant histidine-tagged rat MOG protein (aa 1–125) was pu-
rified from bacterial inclusion bodies (36). MOG peptide 90–110 (SDEGGYTCF-
FRDHSYQEEAA), MOG 1–26 (GQFRVIGPGYPIRALVGDEAELPCRI), 
and MOG 92–106 (DEGGYTCFFRDHSYQ) were synthesized at the core fa-
cility of the Max Planck Institute of Biochemistry (Martinsried, Germany) or 
BioTrend (Köln, Germany). All antigens used in the study were of >95% purity, 
analyzed by silver staining of PAGE (proteins) or HPLC analysis (peptides).
In vitro proliferation assay. Proliferation assays were performed as previ-
ously described (2). Each sample was run in triplicates, the proliferative re-
sponse of which is represented by the mean ± SEM. All assays were replicated 
at least three times.
ELISA. Cytokine measurements and determination of serum titers of MOG-
specific antibodies was performed as previously described (2). Antibodies were 
obtained from BD, except the anti–IL-17 which was obtained from R&D 
Systems. Each assay was repeated at least three times.
Flow cytometric analysis. Single cell suspensions were prepared from spleen, 
lymph node, thymus, or CNS tissue by mechanical disruption via forcing trough 
40-µm cell strainers (BD). Erythrocytes of spleen cell suspensions were lysed by 
hypotonic treatment. CNS infiltrate cells were purified by Percoll gradient cen-
trifugation. Cells were resuspended in Percoll (GE Healthcare) at a density of 
1.035 g/ml and centrifuged over Percoll of a 1.08-g/ml density for 30 min at 
20°C. The interphase was recovered and subjected to FACS analysis. For detec-
tion of cell surface markers by flow cytometric analysis, cells were stained in 
FACS medium (PBS containing 1% BSA and 0.1% NaN3) with different fluo-
rochrome-labeled MAbs. For cytofluorometry, we used the FACSCalibur sys-
tem with CellQuest software (BD), and for analysis we used WinMDI 2.9 
software (Joe Trotter, The Scripps Institute, La Jolla, CA) was used. For intracel-
lular cytokine staining, cells were first surface stained and then fixed and permea-
bilized in 4% PFA/0.1% saponin in Hepes-buffered HBSS, stained intracellularly, 
and washed. Before staining, cells were activated with 50 ng/ml PMA/500 ng/
ml ionomycin in the presence of 5 µg/ml brefeldin A for 4 h. The following   JEM VOL. 206, June 8, 2009 
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Statistics. Differential spontaneous EAE incidence of female to males was 
analyzed by logrank test (by an in-built survival curve analysis function from 
Prism 4 [Graph Pad Software, Inc.]), and the effect of serum transfer on EAE 
development was analyzed by two-way ANOVA. P-values < 0.05 were 
considered to be significant.
Online supplemental material. Fig. S1 shows the nature and encephalito-
genicity of TCR donor clone C3. Fig. S2 shows the TCR expression in 
TCR1640 transgenic mice splenocytes. Fig. S3 illustrates the spontaneous dis-
ease course of individual transgenic TCR1640 animals. Fig. S4 shows the CNS 
messenger RNA expression analysis of spontaneous EAE- and MOG-immu-
nized mice. Fig. S5 shows the efficiency of B cell depletion in TCR1640 mice. 
Video S1 shows one diseased double-transgenic mouse in different EAE stages. 
Table S1 shows a summary of spontaneous EAE in TCR transgenic SJL/J 
mice. Table S2 shows a summary of histological analysis of representative indi-
vidual mice with spontaneous EAE. Table S3 summarizes spontaneous EAE 
incidence and mortality in TCR1640 mice treated with anti-CD20 and control 
isotype antibodies. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20090299/DC1.
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